Sproat M, Pozniak AL, Peeters M, Winters B, Hoetelmans R, Graham NM, Gazzard BG. Antivir Ther. 2005;10(2):357-61
BACKGROUND: In vitro phenotypic resistance studies suggest that the presence of the M184V mutation leads to a reduction in HIV-1 susceptibility to didanosine (ddl). The relevance of this to clinical outcomes remains unclear. In this study, we compared the virological response of ddl- and non-ddl-containing regimens in the presence or absence of the M184V mutation.